$SYRS
Syros Pharmaceuticals, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019027692 Filed on August 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2 2018 Q1
Revenue $462.0K $375.0K $370.0K
YoY Change 23.2% -66.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.200M $3.840M $4.080M
YoY Change 35.42% 10.66% 32.04%
% of Gross Profit
Research & Development $15.48M $11.08M $11.12M
YoY Change 39.64% 10.37% 15.45%
% of Gross Profit
Depreciation & Amortization $650.0K $370.0K $388.0K
YoY Change 75.68% -2.63% 4.86%
% of Gross Profit
Operating Expenses $20.67M $14.92M $15.19M
YoY Change 38.51% 10.43% 19.48%
Operating Profit -$20.21M -$14.55M -$14.82M
YoY Change 38.91% 7.66% 27.62%
Interest Expense $23.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $753.0K $501.0K $358.0K
YoY Change 50.3% 245.52% 265.31%
Pretax Income -$19.46M -$14.05M -$14.46M
YoY Change 38.51% 5.09% 25.52%
Income Tax
% Of Pretax Income
Net Earnings -$19.46M -$14.05M -$14.46M
YoY Change 38.5% 5.06% 25.55%
Net Earnings / Revenue -4211.04% -3745.87% -3908.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$467.0K -$427.2K -$476.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $121.7M $124.4M $121.7M
YoY Change -2.17% 35.96% 72.62%
Cash & Equivalents $101.7M $114.4M $94.33M
Short-Term Investments $20.00M $10.00M $27.40M
Other Short-Term Assets $2.600M $2.600M $1.600M
YoY Change 0.0% 52.94% 6.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $124.4M $127.0M $123.4M
YoY Change -2.07% 36.27% 70.21%
LONG-TERM ASSETS
Property, Plant & Equipment $5.443M $3.300M $3.600M
YoY Change 64.94% -26.67% -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $889.0K $1.200M $1.200M
YoY Change -25.92% -7.69% 20.0%
Total Long-Term Assets $27.46M $4.400M $4.700M
YoY Change 524.07% -24.14% -14.55%
TOTAL ASSETS
Total Short-Term Assets $124.4M $127.0M $123.4M
Total Long-Term Assets $27.46M $4.400M $4.700M
Total Assets $151.8M $131.4M $128.1M
YoY Change 15.55% 32.73% 64.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.759M $1.300M $1.700M
YoY Change 35.31% 0.0% -29.17%
Accrued Expenses $11.70M $8.900M $9.000M
YoY Change 31.46% 71.15% 125.0%
Deferred Revenue $1.700M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $15.33M $17.70M $21.30M
YoY Change -13.38% 152.86% 208.7%
LONG-TERM LIABILITIES
Long-Term Debt $700.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $23.90M $5.000M $2.300M
YoY Change 378.0% 455.56% 130.0%
Total Long-Term Liabilities $24.60M $5.000M $2.300M
YoY Change 392.0% 455.56% 130.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.33M $17.70M $21.30M
Total Long-Term Liabilities $24.60M $5.000M $2.300M
Total Liabilities $39.90M $22.70M $23.60M
YoY Change 75.77% 183.75% 198.73%
SHAREHOLDERS EQUITY
Retained Earnings -$253.5M
YoY Change
Common Stock $365.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.9M $108.7M $104.5M
YoY Change
Total Liabilities & Shareholders Equity $151.8M $131.4M $128.1M
YoY Change 15.55% 32.73% 64.23%

Cashflow Statement

Concept 2019 Q2 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$19.46M -$14.05M -$14.46M
YoY Change 38.5% 5.06% 25.55%
Depreciation, Depletion And Amortization $650.0K $370.0K $388.0K
YoY Change 75.68% -2.63% 4.86%
Cash From Operating Activities -$18.10M -$14.08M -$2.400M
YoY Change 28.55% 19.22% -81.28%
INVESTING ACTIVITIES
Capital Expenditures -$1.320M -$20.00K $152.0K
YoY Change 6500.0% -93.55% -138.0%
Acquisitions
YoY Change
Other Investing Activities $34.00M $17.50M $12.51M
YoY Change 94.29% 66.51% 400.4%
Cash From Investing Activities $32.68M $17.49M $12.36M
YoY Change 86.85% 71.47% 488.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $51.97M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.03M 16.45M 52.17M
YoY Change 295.32% -50.38% 40028.46%
NET CHANGE
Cash From Operating Activities -18.10M -14.08M -2.400M
Cash From Investing Activities 32.68M 17.49M 12.36M
Cash From Financing Activities 65.03M 16.45M 52.17M
Net Change In Cash 79.61M 19.86M 62.13M
YoY Change 300.86% -37.03% -686.68%
FREE CASH FLOW
Cash From Operating Activities -$18.10M -$14.08M -$2.400M
Capital Expenditures -$1.320M -$20.00K $152.0K
Free Cash Flow -$16.78M -$14.06M -$2.552M
YoY Change 19.35% 22.26% -79.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
638000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101740000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49886000
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19978000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49793000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2012000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1417000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
638000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
124368000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
101734000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5443000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3861000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
889000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
881000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3376000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16831000
CY2019Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
920000
CY2019Q2 us-gaap Assets
Assets
151827000
CY2018Q4 us-gaap Assets
Assets
106766000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1759000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3309000
CY2019Q2 syrs Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
10057000
CY2018Q4 syrs Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
13893000
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1661000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1926000
CY2018Q4 syrs Incentive From Lessor Current
IncentiveFromLessorCurrent
392000
CY2019Q2 syrs Financing And Capital Lease Obligations Current
FinancingAndCapitalLeaseObligationsCurrent
226000
CY2018Q4 syrs Financing And Capital Lease Obligations Current
FinancingAndCapitalLeaseObligationsCurrent
9000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1629000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15332000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19529000
CY2018Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
353000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7625000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8276000
CY2019Q2 syrs Financing And Capital Lease Obligations Noncurrent
FinancingAndCapitalLeaseObligationsNoncurrent
708000
CY2018Q4 syrs Financing And Capital Lease Obligations Noncurrent
FinancingAndCapitalLeaseObligationsNoncurrent
22000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16247000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
43000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
365329000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
108712000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41673275
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28510000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
us-gaap Operating Expenses
OperatingExpenses
38098000
us-gaap Operating Expenses
OperatingExpenses
30114000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20208000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14548000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19455000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32892712
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37741646
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-19455000
us-gaap Net Income Loss
NetIncomeLoss
-35916000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31621303
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-14047000
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
27000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19459000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
296100000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253461000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217545000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
111915000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
78586000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151827000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106766000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
666
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
666
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42435497
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33765864
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42435497
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33765864
CY2019Q2 syrs Convertible Preferred Stock Common Shares Issued Upon Conversion
ConvertiblePreferredStockCommonSharesIssuedUponConversion
666000
CY2019Q2 us-gaap Revenues
Revenues
462000
CY2018Q2 us-gaap Revenues
Revenues
375000
us-gaap Revenues
Revenues
916000
us-gaap Revenues
Revenues
745000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15475000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11082000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28037000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22198000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5195000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3841000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10061000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7916000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
20670000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
14923000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1266000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
859000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14047000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35916000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
us-gaap Net Income Loss
NetIncomeLoss
-28510000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
35000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14020000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35909000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28475000
us-gaap Profit Loss
ProfitLoss
-28510000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
764000
us-gaap Share Based Compensation
ShareBasedCompensation
3440000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
115000
syrs Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1668000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
16000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1010000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-697000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
11508000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
64000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28453000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
94000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
46000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
487000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
168000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114676000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4234000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
65324000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
487000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3440000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
900000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3858146
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
900000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
104499000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
245000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1744000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
64018000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2356000
us-gaap Profit Loss
ProfitLoss
-35916000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1104000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
77000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000
us-gaap Share Based Compensation
ShareBasedCompensation
4234000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
542000
syrs Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
595000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1551000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4614000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-916000
syrs Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
-300000
syrs Increase Decrease In Deferred Rent And Lease Incentive
IncreaseDecreaseInDeferredRentAndLeaseIncentive
-174000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38426000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16478000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1911000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
33636000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2486000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29846000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7000
syrs Proceeds From Issuance Of Common Stock And Warrants In Public Offerings And Private Placements Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInPublicOfferingsAndPrivatePlacementsNetOfIssuanceCosts
60362000
syrs Proceeds From Issuance Of Common Stock And Warrants In Public Offerings And Private Placements Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInPublicOfferingsAndPrivatePlacementsNetOfIssuanceCosts
68179000
syrs Proceeds From Issuance Of Convertible Preferred Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts
4638000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64913000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68620000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
54940000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
81988000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50814000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32688000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105754000
us-gaap Interest Paid Net
InterestPaidNet
31000
us-gaap Interest Paid Net
InterestPaidNet
1000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1044000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
syrs Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
997000
syrs Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
28000
syrs Offering Cost Incurred But Not Yet Paid
OfferingCostIncurredButNotYetPaid
3000
syrs Offering Cost Incurred But Not Yet Paid
OfferingCostIncurredButNotYetPaid
2000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="N1_NATURE_BUSINESS"></a><a name="N1_NATURE_BUSINESS"></a>1. Nature of Business</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.42%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syros Pharmaceuticals,&#160;Inc. (the "Company"), a Delaware corporation formed in November 2011, is a biopharmaceutical company&#160;pioneering an understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.42%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals; risks inherent in the development and commercialization of medicines to treat human disease; competition from other companies, many of which are larger and better capitalized; risks relating to obtaining and maintaining necessary intellectual property protection; and the need to obtain adequate additional financing to fund the development of its product candidates and discovery activities. If the Company is unable to raise capital when needed or on favorable terms, it would be forced to delay, reduce, eliminate or out-license certain of its research and development programs or future commercialization rights to its product candidates.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant annual net operating losses in every year since its inception. It expects to continue to incur significant and increasing net operating losses for at least the next several years. The Company&#8217;s net losses were $62.3 million, $54.0&#160;million and $47.7 million for the years ended December&#160;31, 2018, 2017 and 2016, respectively. As of June&#160;30,&#160;2019, the Company had an accumulated deficit of $253.5&#160;million. The Company has not generated any revenues from product sales, has not completed the development of any product candidate and may never have a product candidate approved for commercialization. The Company has financed its operations to date primarily through the sale of equity securities. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. The Company&#8217;s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders' equity and working&#160;capital.&#160;In April 2019, the Company raised $70.0 million in gross proceeds from issuance of equity securities in two concurrent public offerings. <font style="color:#000000;">The Company believes that its cash, cash equivalents and marketable securities of $121.7 million as of </font>June&#160;30,&#160;2019<font style="color:#000000;"> will be sufficient to allow the Company to fund its current operating plan for a period of at least 12 months past the issuance date of these unaudited interim condensed consolidated financial statements</font>. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:7.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. Management&#8217;s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, stock-based compensation expense, accrued expenses and income taxes. Actual results may differ from those estimates or assumptions.</p>
CY2019Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1000000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
687000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4252000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3824000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3935000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-62300000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-54000000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-47700000
CY2019Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
121700000
CY2019Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
70000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8647368
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9286000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1700000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10202000
syrs Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
syrs Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
916000
CY2019Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
121714000
CY2019Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2019Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
121718000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
99682000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
99679000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q2 syrs Number Of Investments Adjusted For Other Than Temporary Declines In Fair Value
NumberOfInvestmentsAdjustedForOtherThanTemporaryDeclinesInFairValue
0
CY2019Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
4000000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114386000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32205000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
193000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2019Q2 syrs Accrued External Research And Preclinical Development Expenses
AccruedExternalResearchAndPreclinicalDevelopmentExpenses
6725000
CY2018Q4 syrs Accrued External Research And Preclinical Development Expenses
AccruedExternalResearchAndPreclinicalDevelopmentExpenses
10119000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4049000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
27709000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
44456000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1955000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2985000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
450000
CY2019Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0932
CY2019Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2019Q2 syrs Number Of Underwriting Agreements
NumberOfUnderwritingAgreements
2
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
618000
CY2019Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
927000
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
171000
CY2019Q1 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2019Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1000000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17285000
CY2019Q2 us-gaap Incentive From Lessor
IncentiveFromLessor
9295000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
17876000
CY2019Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
152000
CY2019Q2 us-gaap Finance Lease Liability Payments Due In Rolling Year Two
FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
304000
CY2019Q2 us-gaap Finance Lease Liability Payments Due In Rolling Year Three
FinanceLeaseLiabilityPaymentsDueInRollingYearThree
300000
CY2019Q2 us-gaap Finance Lease Liability Payments Due In Rolling Year Four
FinanceLeaseLiabilityPaymentsDueInRollingYearFour
299000
CY2019Q2 us-gaap Finance Lease Liability Payments Due In Rolling Year Five
FinanceLeaseLiabilityPaymentsDueInRollingYearFive
51000
CY2019Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1106000
CY2019Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
172000
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
934000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
437000
us-gaap Operating Lease Cost
OperatingLeaseCost
490000
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
61000
CY2019Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
23000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
31000
CY2019Q2 syrs Finance Lease Cost
FinanceLeaseCost
84000
syrs Finance Lease Cost
FinanceLeaseCost
108000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
330000
us-gaap Operating Lease Payments
OperatingLeasePayments
659000
CY2019Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
76000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
124000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0937
CY2019Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M26D
CY2019Q2 syrs Underwriting Discounts And Commissions And Estimated Offering Expenses Payable
UnderwritingDiscountsAndCommissionsAndEstimatedOfferingExpensesPayable
5000000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3732643
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1096500
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2300
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
85843
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4741000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1919931
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.88
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.73
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.38
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6966000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3601000
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9800
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2356000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1744000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.12
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.97
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1694000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4234000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3440000

Files In Submission

Name View Source Status
0001564590-19-027692-index-headers.html Edgar Link pending
0001564590-19-027692-index.html Edgar Link pending
0001564590-19-027692.txt Edgar Link pending
0001564590-19-027692-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syrs-10q_20190630.htm Edgar Link pending
syrs-20190630.xml Edgar Link completed
syrs-20190630.xsd Edgar Link pending
syrs-20190630_cal.xml Edgar Link unprocessable
syrs-20190630_def.xml Edgar Link unprocessable
syrs-20190630_lab.xml Edgar Link unprocessable
syrs-20190630_pre.xml Edgar Link unprocessable
syrs-ex311_10.htm Edgar Link pending
syrs-ex312_8.htm Edgar Link pending
syrs-ex321_6.htm Edgar Link pending
syrs-ex322_7.htm Edgar Link pending